IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer Comparison
Peer Comparison
Performance
Performance Report
Eris Lifesciences IPO is a Book Building listing on BSE,NSE exchange, with an ipo size of ₹ 1741.16 Cr. The company is based in Ahmedabad and caters to Pharmaceutical sector. Axis Capital , Citigroup Global Markets India , Credit Suisse Securities (India) are the merchant bankers of Eris Lifesciences IPO. It is a MainBoard IPO which filed its Draft Red Herring Prospectus (DRHP) on 8th February 2017.
Eris Lifesciences IPO posted revenues of ₹ 724.96 Cr. and PAT of ₹ 241.90 Cr. in FY25 on annualised basis.
Revenue:
₹ 724.96 Cr.
EBITDA Margin:
39.69
% 
Net Worth: ₹ 539.92 Cr.
Market Capitalisation:
[●]
P/E:
34.00 times
P/BV: [●]
EV/EBITDA: -0.01 times
Financial results of Eris Lifesciences IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | FY17 | FY16 | FY15 | ||
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 641.00 | 397.36 | 357.29 | ||
| Net Worth | 539.92 | 299.24 | 265.67 | ||
| Total Debt | 0.49 | [●] | 0.50 | ||
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
724.96 | 597.02 | 545.56 | ||
EBITDA
EBITDA on annualised basis |
287.75 | 174.92 | 124.95 | ||
PAT
PAT on annualised basis |
241.90 | 134.86 | 89.26 | ||
Eris Lifesciences IPO PAT Margin is 33.37 % , ROCE (Return on Capital Employed) is [●] % as per latest financial. The below table shows Eris Lifesciences IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | FY17 | FY16 | FY15 |
|---|---|---|---|
| EBITDA Margin (%) | 39.69 | 29.30 | 22.90 |
| PAT Margin (%) | 33.37 | 22.59 | 16.36 |
| EPS (₹) | 17.61 | 10.03 | 6.06 |
| ROE (%) | 44.80 | 45.07 | 33.60 |
| ROCE (%) | [●] | [●] | [●] |
| ROA (%) | 37.74 | 33.94 | 24.98 |
| Debt to Equity | 0.00 | [●] | 0.00 |
The market Capitalisation of Eris Lifesciences IPO is ₹ 0.00 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Eris Lifesciences IPO prospectus highlights an Return on Equity (ROE) of 44.80 % , Return on Assets (ROA) of 37.74 %, and an EBITDA Margin of 39.69 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Eris Lifesciences IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Eris Lifesciences IPO is ₹ 0.00 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Eris Lifesciences IPO has a Price-to-Earnings (PE) ratio of 34.00 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Eris Lifesciences IPO reported revenue of ₹ 744.07 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Eris Lifesciences IPO provide insights into sales growth, market demand, and business scalability.
Eris Lifesciences recorded an EBITDA of ₹ 287.75 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Eris Lifesciences Profit After Tax (PAT) is ₹ 241.90 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 724.96 Cr.
EBITDA Margin:
39.69
%
Net Worth: ₹ 539.92 Cr.
Market Capitalisation:
[●]
P/E:
34.00 times
P/BV: [●]
EV/EBITDA:
[●]
Eris Lifesciences operates in Pharmaceutical and Developer Manufacturer And Commercializer Of Branded Pharmaceutical Produ. The Issue is listed on BSE,NSE in Jun, 2017. Eris Lifesciences IPO size was 1741.16 with Issue price of 603.00 .
Merchant Banker(s) of Eris Lifesciences IPO: Axis Capital Limited , Citigroup Global Markets India Private Limited , Credit Suisse Securities (India) Private Limited
Eris Lifesciences IPO subscription was 3.29 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Eris Lifesciences IPO listed at a listing price of 601.05 against the offer price of 603.00.
The current market price of Eris Lifesciences is 1762.80.
Why Us?
